Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03813186 · ClinicalTrials.gov registry record · Phase 1
Effect of Food on Blood Levels of ASTX727
A Phase 1 study, sponsored by Astex Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 18
- Enrollment target
NCT03813186 is a Phase 1 study that has completed, run by Astex Pharmaceuticals. The registered enrollment target is 18 participants.
The verdict
NCT03813186, a Phase 1 study, has completed, sponsored by Astex Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 18 participants
- Enrollment target
Study Summary
This study is designed to examine blood levels of ASTX727, a fixed-dose combination tablet containing the combination of cedazuridine (100 mg) and decitabine (35 mg), when given under fed versus fasted conditions to participants with myelodysplastic syndromes (MDS), including refractory anemia with excess blasts in transformation or chronic myelomonocytic leukemia (CMML), or acute myeloid leukemia (AML). This study will also assess the safety of ASTX727.
Interventions
- DRUG ASTX727 + Day 2 Food
- DRUG ASTX727 + Day 4 Food
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2018-11-08 |
| Est. Completion | 2019-12-16 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03813186
The ClinicalTrials.gov registry entry for NCT03813186 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Astex Pharmaceuticals, which has 38 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ASTX727 + Day 2 Food is the first listed.
NCT03813186 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03813186 about?
NCT03813186 is a clinical study titled "Effect of Food on Blood Levels of ASTX727". This study is designed to examine blood levels of ASTX727, a fixed-dose combination tablet containing the combination of cedazuridine (100 mg) and decitabine (35 mg), when given under fed versus fasted conditions to participants with myelodysplastic syndromes (MDS), including refractory anemia with ...
What is the current status of trial NCT03813186?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 18 participants. The study started on 2018-11-08. Estimated completion is 2019-12-16.
What interventions are being tested in trial NCT03813186?
The interventions under investigation include: ASTX727 + Day 2 Food (DRUG), ASTX727 + Day 4 Food (DRUG).
Who is sponsoring clinical trial NCT03813186?
This trial is sponsored by Astex Pharmaceuticals, which has 38 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.